Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Afuresertib hydrochloride by Laekna for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Afuresertib hydrochloride is under clinical development by Laekna and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...
Data Insights
Afuresertib hydrochloride by Laekna for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Afuresertib hydrochloride is under clinical development by Laekna and currently in Phase III for Human Epidermal Growth Factor Receptor 2...